Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Profit After Tax rose 2027.85% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.6 million, marking a year-over-year increase of 5235.89%. This contributed to the annual value of $163.9 million for FY2024, which is 12950.43% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Profit After Tax stood at $52.8 million, which was up 2027.85% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Profit After Tax ranged from a high of $56.7 million in Q1 2025 and a low of -$30.8 million during Q3 2023
  • For the 5-year period, Catalyst Pharmaceuticals' Profit After Tax averaged around $27.3 million, with its median value being $25.5 million (2022).
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 23523.83% in 2023, then skyrocketed by 24264.73% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Profit After Tax (Quarter) stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then soared by 36.8% to $34.8 million in 2023, then soared by 60.53% to $55.9 million in 2024, then dropped by 5.64% to $52.8 million in 2025.
  • Its last three reported values are $52.8 million in Q3 2025, $52.1 million for Q2 2025, and $56.7 million during Q1 2025.